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ABSTRACT
Objectives To investigate the efficacy and safety of 
ixekizumab for up to 52 weeks in two phase 3 studies of 
patients with active radiographic axial spondyloarthritis 
(r- axspa) who were biological disease- modifying 
antirheumatic drug (bDMaRD)- naive (COasT- V) or tumour 
necrosis factor inhibitor (TnFi)- experienced (COasT- W).
Methods adults with active r- axspa were randomised 
1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (iXe 
Q2W) or 4 weeks (iXe Q4W), placebo (PBO) or 40 
mg adalimumab Q2W (aDa) in COasT- V and 1:1:1 
(n=316) to iXe Q2W, iXe Q4W or PBO in COasT- W. at 
week 16, patients receiving ixekizumab continued their 
assigned treatment; patients receiving PBO or aDa were 
rerandomised 1:1 to iXe Q2W or iXe Q4W (PBO/iXe, 
aDa/iXe) through week 52.
Results in COasT- V, assessment of spondyloarthritis 
international society 40 (asas40) responses rates 
(intent- to- treat population, non- responder imputation) at 
weeks 16 and 52 were 48% and 53% (iXe Q4W); 52% 
and 51% (iXe Q2W); 36% and 51% (aDa/iXe); 19% 
and 47% (PBO/iXe). Corresponding asas40 response 
rates in COasT- W were 25% and 34% (iXe Q4W); 
31% and 31% (iXe Q2W); 14% and 39% (PBO/iXe). 
Both ixekizumab regimens sustained improvements in 
disease activity, physical function, objective markers of 
inflammation, Qol, health status and overall function 
up to 52 weeks. safety through 52 weeks of ixekizumab 
was consistent with safety through 16 weeks.
Conclusion The significant efficacy demonstrated 
with ixekizumab at week 16 was sustained for up to 
52 weeks in bDMaRD- naive and TnFi- experienced 
patients. bDMaRD- naive patients initially treated with 
aDa demonstrated further numerical improvements after 
switching to ixekizumab. safety findings were consistent 
with the known safety profile of  
ixekizumab.
Trial registration number nCT02696785/ 
nCT02696798.
InTROduCTIOn
Axial spondyloarthritis (axSpA) is a chronic inflam-
matory condition comprising non- radiographic 
Key messages
What is already known about this subject?
 ► Ixekizumab was superior to placebo at week 16 
for treating the signs and symptoms of active 
radiographic axial spondyloarthritis (r- axSpA) 
in two phase 3 trials in patients who were 
biological disease- modifying antirheumatic drug 
(bDMARD)- naive (COAST- V) or tumour necrosis 
factor inhibitor (TNFi)- experienced (prior 
inadequate response or intolerance to one or 
two TNFi; COAST- W).
What does this study add?
 ► The significant improvements observed with 
ixekizumab at week 16 were sustained for up 
to 52 weeks in bDMARD- naive (COAST- V) and 
TNFi- experienced patients (COAST- W); results 
were similar between two ixekizumab regimens 
(80 mg every 2 or every 4 weeks) across 
endpoints. In COAST- V, bDMARD- naive patients 
who were initially treated with adalimumab 
for 16 weeks demonstrated further numerical 
improvements through week 52 after switching 
to ixekizumab.
 ► COAST- W is the first phase 3 study of a 
bDMARD in an exclusively TNFi- experienced 
patient population and provides robust 
information on the long- term efficacy and 
safety of ixekizumab in this population.
 ► Adverse events were consistent with the known 
safety profile of ixekizumab.
How might this impact on clinical practice or 
future developments?
 ► The findings from COAST- V and COAST- W 
suggest that ixekizumab could be a longer- 
term treatment option for patients with 
axSpA, regardless of prior experience with 
TNFi. The additional numeric improvement in 
adalimumab- treated patients after switching to 
ixekizumab is of particular interest and deserves 
further exploration.
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axSpA and radiographic axSpA (r- axSpA). The latter, also 
known as ankylosing spondylitis (AS), is characterised by inflam-
matory back pain and radiographic evidence of damage to the 
sacroiliac joint.1 These manifestations, and peripheral musculo-
skeletal and extra- articular signs and symptoms, may contribute 
to limited mobility, progressive disability and decreased quality 
of life (QoL).2 3 Biological disease- modifying antirheumatic 
drugs (bDMARDs), including tumour necrosis factor inhibitors 
(TNFi)4 5 and an interleukin (IL)- 17A antagonist,5 are recom-
mended for managing patients with axSpA who do not respond 
to or tolerate non- steroidal anti- inflammatory drugs (NSAIDs). 
However, up to 40% of patients fail to achieve satisfactory 
disease control with TNFi,6 and treatment with TNFi may be 
contraindicated in other patients.7
The IL-17 signalling pathway plays a key role in the patho-
genesis of axSpA.8 9 Ixekizumab, a high- affinity monoclonal 
antibody that selectively targets IL- 17A, is approved for treating 
active psoriatic arthritis and moderate- to- severe plaque psoriasis 
and has demonstrated efficacy in two phase 3 trials in patients 
with r- axSpA who were bDMARD- naive (COAST- V) or TNFi- 
experienced (prior inadequate response or intolerance to TNFi; 
COAST- W).10 11 In both studies, ixekizumab resulted in signifi-
cantly greater improvement versus placebo (PBO) at week 16 
for measures of disease activity (including the primary endpoint 
of Assessment of SpondyloArthritis international Society 40 
response (ASAS40)), function, QoL and spinal inflammation.
Here, we evaluated the sustainability of improvements observed 
at week 16 for treatment of r- axSpA with ixekizumab 80 mg every 
4 or 2 weeks (IXE Q4W or IXE Q2W) up to week 52 in COAST- V 
and COAST- W. We also evaluated the safety of ixekizumab for 
up to 52 weeks, with a specific focus on overall safety, including 
events of special interest such as injection site reactions (ISRs) and 
candidiasis, and extra- articular manifestations such as inflamma-
tory bowel disease (IBD), anterior uveitis (AU) and psoriasis.
MATeRIAlS And MeTHOdS
Study design
COAST- V10 and COAST- W11 are phase 3, multicentre, 
randomised, double- blind, active- controlled (COAST- V only) 
and PBO- controlled, 52- week trials, followed by an optional 
2- year extension study.
All patients provided written informed consent.
Patient and public involvement
Patients were not involved in the design or conduct of the study, 
development of outcomes or dissemination of study results.
Patients
Patient eligibility criteria have been described previously.10 11 
Patients were to be ≥18 years of age, have an established diagnosis 
of r- axSpA and meet ASAS criteria (with central reading of radio-
graphic sacroiliitis).12 Patients in COAST- W were required to have 
discontinued one or two TNFi because of intolerance or inade-
quate response; COAST- V only included bDMARD- naive patients.
Treatment protocol
Study procedures for COAST- V and COAST- W have been 
described elsewhere.10 11 Patients in COAST- V were randomised 
1:1:1:1 to PBO, adalimumab 40 mg (ADA) Q2W, IXE Q2W or 
IXE Q4W. ADA represents an active reference group; the study 
was not powered to test equivalence/non- inferiority of the active 
treatment groups to each other, including ixekizumab versus 
ADA. Patients in COAST- W were randomised 1:1:1 to PBO, IXE 
Q2W or IXE Q4W. In both trials, patients assigned ixekizumab 
were further randomised 1:1 to a 160 mg or 80 mg starting dose.
Patients completing week 16 entered a dose double- blind 
extended treatment period (ETP; weeks 16 to 52). During this 
period, patients originally randomised to PBO or ADA (COAST- V 
only) were rerandomised 1:1 to IXE Q2W or IXE Q4W (160 mg 
starting dose for patients switching from PBO, 80 mg starting dose 
for patients switching from ADA). Patients originally randomised 
to IXE Q2W or IXE Q4W continued these regimens.
Assessments
Efficacy
Efficacy assessments were made at weeks 20, 24, 28, 32, 36, 44 
and 52 in the ETP, except where specified below.
Categorical efficacy endpoints assessed included the propor-
tion of patients achieving ASAS40,13 ASAS20, ASAS partial remis-
sion, Ankylosing Spondylitis Disease Activity Score (ASDAS)14 
low disease activity (score <2.1), ASDAS inactive disease (score 
<1.3), ASDAS clinically important improvement (≥1.1 change 
from baseline), ASDAS major improvement (≥2.0 change from 
baseline or reached a minimal ASDAS score of 0.6361) and 
≥50% improvement in Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI50).15 Continuous endpoints included 
changes from baseline in ASDAS, BASDAI, Bath Ankylosing 
Spondylitis Functional Index (BASFI),16 Medical Outcomes 
Study Short Form 36 (SF-36) health survey Physical Component 
Score (PCS),17 ASAS Health Index (ASAS HI),18 19 Spondyloar-
thritis Research Consortium of Canada (SPARCC) MRI20 of the 
spine and sacroiliac joint (the latter in COAST- V only) and serum 
C reactive protein (CRP) concentrations. After week 16, SF-36 
PCS and ASAS HI assessments were performed at weeks 36 and 
52; MRI assessments were performed at week 16 in both studies 
and at week 52 in COAST- V only. MRI from baseline, week 
16 and week 52 were read in a single campaign. Concomitant 
NSAID use and ASAS- NSAID21 scores were assessed.
Safety
Safety assessments included the evaluation of adverse events 
(AEs; per the Medical Dictionary for Regulatory Activities) and 
treatment- emergent antidrug antibodies (TE- ADAs).10 11 Cerebro-
cardiovascular events and suspected IBD were adjudicated by an 
independent clinical event committee. All IBD events were adjudi-
cated by an external committee following EPIMAD criteria.22
At every visit, patients were evaluated for any symptoms of 
AU; AU events were confirmed by an ophthalmologist. Psoriasis 
and IBD were not proactively evaluated, but new onset or flares 
were recorded as AEs.
Statistical analysis
Efficacy analyses through 52 weeks were performed on the intent- 
to- treat population (ITT; IXE Q4W, IXE Q2W), which included 
all patients initially randomised to ixekizumab, and the ETP popu-
lation, which included all patients who received ≥1 dose of ixeki-
zumab during the ETP. Considering the consistent performance of 
the IXE Q4W and IXE Q2W regimens, data for patients in the 
ETP who were initially randomised to PBO or ADA were analysed 
as single groups (PBO/IXE or ADA/IXE), regardless of which ixeki-
zumab dose they received during the ETP. Safety analyses were 
performed on the ETP population and on the all ixekizumab expo-
sure safety population (IXE Q4W, IXE Q2W), which included all 
patients who received ≥1 dose of ixekizumab at any time during 
the 52- week study period.
No between- treatment group comparisons were made for ETP 
data. For primary analyses of the ITT and ETP populations, the 
most conservative approach was followed, where missing data 
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Figure 1 Patient disposition: (A) COAST- V; (B) COAST- W. ADA, adalimumab; bDMARD, biological disease- modifying antirheumatic drug; extended 
treatment period, dose double- blind extended treatment period; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 
weeks; PBO, placebo; TNFi, tumour necrosis factor inhibitor.
were imputed using non- responder imputation (NRI) for categor-
ical variables and modified baseline observation carried forward 
(mBOCF, a more stringent method of analysis than last observation 
carried forward) for continuous variables. For secondary analyses 
of ITT data, missing data were imputed using modified NRI for 
categorical variables and multiple imputation for continuous vari-
ables. ITT data were also analysed as observed. SF-36 PCS data are 
reported as t- scores, based on 2009 US general population norms.
Statistical analyses were performed using SAS V.9.2 or higher 
(SAS Institute).
ReSulTS
Patients
The majority of patients in COAST- V (309/329; 93.9%) and 
COAST- W (250/281; 89.0%) who entered the ETP completed 
week 52 (figure 1). Of the patients initially randomised to ixeki-
zumab, 146/164 (89.0%) in COAST- V and 169/212 (79.7%) 
in COAST- W completed week 52. The most common reason 
for discontinuation was patient withdrawal (n=11; 3.3%) in 
COAST- V and lack of efficacy (n=11; 3.9%) in COAST- W.
Demographics and baseline clinical characteristics for the ETP 
populations were similar between treatment groups within each 
study (online supplementary table S1) and similar to those of the 
ITT populations.10 11 Baseline and historical peripheral/extra- 
articular manifestations of axSpA are summarised in online supple-
mentary table S2.
efficacy
Among patients continuously treated with ixekizumab, week 16 
ASAS40 response rates were sustained for up to 52 weeks (figure 2, 
table 1). Week 52 ASAS40 response rates were 53.1% (IXE Q4W) 
and 50.6% (IXE Q2W) in COAST- V and 34.2% (IXE Q4W) and 
30.6% (IXE Q2W) in COAST- W. Patients randomised to PBO 
and rerandomised to ixekizumab at week 16 (PBO/IXE) showed 
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Figure 2 Proportion of patients achieving ASAS40, ASAS20 and ASDAS <2.1 responses through 52 weeks in COAST- V (A, C, E) and COAST- W (B, D, 
F). ITT population. Missing data were imputed using NRI. ADA represents an active reference group; the study was not powered to test equivalence 
or non- inferiority of the active treatment groups to each other, including ixekizumab versus ADA. *ASDAS <2.1 indicates low disease activity. ADA, 
adalimumab; ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; bDMARD, biological 
disease- modifying antirheumatic drug; ITT, intent to treat; IXE Q4W, ixekizumab 80 mg every 4 weeks; IXE Q2W, ixekizumab 80 mg every 2 weeks; 
NRI, non- responder imputation; PBO, placebo; TNFi, tumour necrosis factor inhibitor.
rapid improvement in ASAS40 response rates after switching to 
ixekizumab (figure 3, table 2); week 52 response rates (46.5% 
in COAST- V, 38.7% in COAST- W) were numerically similar to 
those in patients initially randomised to ixekizumab. In COAST- V, 
patients randomised to ADA showed further numerical improve-
ments in ASAS40 response rates (36.0% at week 16, 51.2% at 
week 52) after switching to ixekizumab (figure 3A, table 2); week 
52 response rates were numerically similar to those in patients 
initially randomised to ixekizumab. Among ADA/IXE patients who 
were ASAS40 non- responders at week 16, but ASAS40 responders 
at week 52, 47.4% were ASAS20 non- responders and 52.6% were 
ASAS20 responders at week 16.
Consistent with the ASAS40 findings, week 16 improvements in 
ASAS20 response rates were sustained for up to 52 weeks among 
patients continuously treated with ixekizumab in both studies 
(figure 2C and D). Week 16 improvements in other measures 
of disease activity were sustained for up to 52 weeks, including 
changes from baseline in ASDAS and BASDAI, and achievement 
of ASAS partial remission, ASDAS improvement categories (low 
disease activity (figure 2), inactive disease, clinically important 
improvement and major improvement) and BASDAI50 (table 1). 
Improvements in patient function at week 16 (change from base-
line in BASFI) were sustained for up to 52 weeks in patients 
continuously treated with ixekizumab, as were improvements in 
measures of QoL (change from baseline in SF-36 PCS) and health 
functioning (change from baseline in ASAS HI) (table 1). Week 
16 improvements in spinal MRI and objective inflammation were 
sustained for up to 52 weeks per SPARCC spine and sacroiliac joint 
scores (assessed beyond week 16 in COAST- V only) and changes 
from baseline in CRP (table 1).
In COAST- V, patients randomised to ADA showed further 
numerical improvements in most efficacy endpoints on switching 
to ixekizumab (table 2).
Results from secondary analyses (online supplementary table 
S3 and S4) were consistent with the primary analyses (NRI and 
mBOCF).
Concomitant NSAID and ASAS- NSAID findings are 
summarised in online supplementary table S5.
Safety
ETP population (weeks 16 to 52)
Overall, 201 (61.1%) patients in COAST- V and 179 (63.7%) 
patients in COAST- W reported treatment- emergent adverse 
events (TEAEs) during the ETP (table 3). Most TEAEs were of 
mild or moderate severity. Eight (2.4%) patients in COAST- V 
and 10 (3.6%) patients in COAST- W discontinued treatment 
because of an AE. The most common TEAEs were nasopharyn-
gitis, ISRs and upper respiratory tract infection. Serious adverse 
events (SAEs) occurred in 18 (5.5%) patients in COAST- V and 9 
(3.2%) patients in COAST- W; the frequency of SAEs was similar 
between ixekizumab regimens. The only SAE reported by more 
than one patient was bradycardia (n=2 patients; neither SAE 
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Figure 3 Proportion of patients initially randomised to PBO or ADA achieving ASAS40 responses on treatment with ixekizumab from week 16 
through week 52 in COAST- V (A) and COAST- W (B). ETP population. Missing data were imputed using NRI. ADA, adalimumab; ASAS, Assessment of 
SpondyloArthritis international Society; bDMARD, biological disease- modifying antirheumatic drug; ETP, dose double- blind extended treatment period; 
IXE, ixekizumab; NRI, non- responder imputation; PBO, placebo; TNFi, tumour necrosis factor inhibitor.
Table 2 Week 16* and 52 efficacy endpoints for PBO and ADA patients rerandomised to ixekizumab at week 16: COAST- V and COAST- W (ETP 
population: NRI, modified baseline observation carried forward)
COAST- V (bdMARd- naive) COAST- W (TnFi- experienced)
PBO/IXe
(n=86)
AdA/IXe
(n=86)
PBO/IXe
(n=93)
Patients achieving response, n (%)
NRI Week 16 Week 52 Week 16 Week 52 Week 16 Week 52
  ASAS40 16 (18.6) 40 (46.5) 31 (36.0) 44 (51.2) 13 (14.0) 36 (38.7)
  ASAS20 35 (40.7) 58 (67.4) 52 (60.5) 58 (67.4) 31 (33.3) 50 (53.8)
  ASAS partial remission 7 (8.1) 16 (18.6) 13 (15.1) 18 (20.9) 1 (1.1) 9 (9.7)
  ASDAS clinically important 
improvement
20 (23.3) 55 (64.0) 48 (55.8) 55 (64.0) 18 (19.4) 49 (52.7)
  ASDAS major improvement 4 (4.7) 27 (31.4) 21 (24.4) 28 (32.6) 4 (4.3) 25 (26.9)
  ASDAS<2.1 (low disease activity) 11 (12.8) 35 (40.7) 33 (38.4) 41 (47.7) 5 (5.4) 27 (29.0)
  ASDAS<1.3 (inactive disease) 2 (2.3) 14 (16.3) 14 (16.3) 15 (17.4) 1 (1.1) 6 (6.5)
  BASDAI50 15 (17.4) 40 (46.5) 28 (32.6) 39 (45.3) 10 (10.8) 35 (37.6)
Mean change from baseline (SD)
mBOCF† Week 16 Week 52 Week 16 Week 52 Week 16 Week 52
  ASDAS −0.6 (0.8) −1.6 (1.0) −1.3 (1.2) −1.5 (1.1) −0.2 (1.1) −1.4 (1.3)
  BASDAI −1.5 (1.7) −2.9 (2.1) −2.4 (2.3) −3.0 (2.3) −1.0 (2.1) −2.7 (2.6)
  BASFI −1.3 (1.8) −2.4 (2.2) −2.2 (2.2) −2.7 (2.3) −0.7 (2.1) −2.2 (2.7)
  SF-36 PCS‡ 4.2 (6.3) 7.7 (8.0) 6.6 (7.2) 7.7 (8.0) 1.0 (7.2) 6.2 (8.7)
  ASAS Health Index −1.4 (2.5) −2.5 (3.3) −2.4 (3.1) −2.9 (3.6) −0.9 (3.2) −2.4 (3.6)
  SPARCC MRI spine score§ −1.1 (5.9) −8.5 (14.6) −12.6 (21.4) −13.9 (21.2) NA NA
  SPARCC MRI sacroiliac joint score¶ 0.76 (5.4) −2.7 (6.2) −2.8 (8.4) −3.0 (9.0) NA NA
  CRP, mg/L −1.0 (22.9) −11.2 (22.3) −8.4 (17.3) −9.4 (17.0) 6.8 (29.9) −9.7 (25.8
*Except for ASAS partial remission (both studies), ASDAS clinically important improvement (both studies), ASDAS major improvement (both studies), ASDAS <1.3 (COAST- W) and 
BASDAI50 (COAST- W), all week 16 data have been previously reported.10 11
† For patients who discontinued study drug because of an adverse event, the baseline observation was carried forward to the corresponding timepoint for evaluation. For 
patients discontinuing study drug for any other reason, the last non- missing observation before discontinuation was carried forward to the corresponding time point for 
evaluation.
‡ SF- 36PCS data are reported as t- scores, based on 2009 US general population norms.
§ Observed data only (not assessed after week 16 in COAST- W). COAST- V: week 16, n=81 (PBO/IXE) and n=80 (ADA/IXE); week 52, n=76 (PBO/IXE) and n=76 (ADA/IXE). 
COAST- W: week 16, n=49 (IXE Q4W) and n=45 (IXE Q2W).
¶ Observed data only (not assessed in COAST- W). COAST- V: week 16, n=81 (PBO/IXE) and n=80 (ADA/IXE); week 52, n=76 (PBO/IXE) and n=76 (ADA/IXE).
ADA, adalimumab; ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease- modifying antirheumatic drug; CRP, C reactive protein; ETP, dose double- 
blind extended treatment period; mBOCF, modified baseline observation carried forward; NA, not applicable; NRI, non- responder imputation;PBO, placebo; SF-36 PCS, Medical 
Outcomes Study 36- item Short- Form Health Survey Physical Component Score; IXE Q2W, ixekizumab 80 mg every 2 weeks; IXE Q4W, ixekizumab 80 mg every 4 weeks; TNFi, 
tumour necrosis factor inhibitor.
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Table 3 Safety summary: COAST- V and COAST- W (ETP population (weeks 16 to 52) and all ixekizumab exposure safety population (weeks 0 to 
52))
COAST- V (bdMARd- naive)
eTP population
(weeks 16–52)
COAST- W (TnFi- experienced)
eTP population
(weeks 16–52)
COAST- V+COAST W
All ixekizumab exposure safety pop-
ulation
(weeks 0–52)
PBO/
IXe
(n=86)
n (%)
AdA/
IXe
(n=86)
n (%)
IXe Q4W/
IXe Q4W
(n=78)
n (%)
IXe Q2W/
IXe Q2W
(n=79)
n (%)
PBO/
IXe
(n=93)
n (%)
IXe Q4W/
IXe Q4W
(n=98)
n (%)
IXe Q2W/
IXe Q2W
(n=90)
n (%)
Total
IXe Q4W
(n=327)
n (%) (IR*)
Total
IXe Q2W
(n=314)
n (%) (IR*)
Exposure, patient- years 58.5 51.7 51.9 53.2 59.6 64.1 58.2 259.4 250.8
Any TEAE 57 (66.3) 50 (58.1) 50 (64.1) 44 (55.7) 52 (55.9) 69 (70.4) 58 (64.4) 234 (71.6) (90.2) 217 (69.1) (86.5)
  Mild 31 (36.0) 32 (37.2) 34 (43.6) 28 (35.4) 21 (22.6) 30 (30.6) 24 (26.7) 115 (35.2) (44.3) 97 (30.9) (38.7)
  Moderate 22 (25.6) 15 (17.4) 13 (16.7) 13 (16.5) 23 (24.7) 33 (33.7) 30 (33.3) 101 (30.9) (38.9) 98 (31.2) (39.1)
  Severe 4 (4.7) 3 (3.5) 3 (3.8) 3 (3.8) 8 (8.6) 6 (6.1) 4 (4.4) 18 (5.5) (6.9) 22 (7.0) (8.8)
Discontinuation due to AE 2 (2.3) 3 (3.5) 1 (1.3) 2 (2.5) 1 (1.1) 4 (4.1) 5 (5.6) 17 (5.2) (6.6) 17 (5.4) (6.8)
SAEs 4 (4.7) 7 (8.1) 4 (5.1) 3 (3.8) 6 (6.5) 2 (2.0) 1 (1.1) 17 (5.2) (6.6) 19 (6.1) (7.6)
Death 0 0 0 0 0 0 0 0 1 (0.3) (0.4)
Most common TEAEs†
  Nasopharyngitis 17 (19.8) 7 (8.1) 8 (10.3) 7 (8.9) 3 (3.2) 3 (3.1) 4 (4.4) 37 (11.3) (14.3) 25 (8.0) (10.0)
  Injection site reaction 8 (9.3) 8 (9.3) 3 (3.8) 6 (7.6) 3 (3.2) 2 (2.0) 5 (5.6) 13 (4.0) (5.0) 30 (9.6) (12.0)
  Upper respiratory tract infection 4 (4.7) 4 (4.7) 4 (5.1) 8 (10.1) 5 (5.4) 4 (4.1) 8 (8.9) 29 (8.9) (11.2) 27 (8.6) (10.8)
AEs of special interest
  Grade 3 or 4 neutropenia 0 0 0 0 0 0 0 1 (0.3) (0.4) 0
  Infections 34 (39.5) 19 (22.1) 25 (32.1) 25 (31.6) 32 (34.4) 29 (29.6) 33 (36.7) 134 (41.0) (51.7) 118 (37.6) (47.1)
   Serious infections 1 (1.2) 1 (1.2) 0 1 (1.3) 2 (2.2) 0 1 (1.1) 3 (0.9) (1.2) 7 (2.2) (2.8)
   Candida infection 2 (2.3) 0 0 0 0 2 (2.0) 0 4 (1.2) (1.5) 1 (0.3) (0.4)
  Injection site reactions 15 (17.4) 13 (15.1) 5 (6.4) 9 (11.4) 8 (8.6) 3 (3.1) 7 (7.8) 30 (9.2) (11.6) 54 (17.2) (21.5)
  Allergic reactions/ hypersensitivities 4 (4.7) 4 (4.7) 4 (5.1) 2 (2.5) 2 (2.2) 6 (6.1) 4 (4.4) 20 (6.1) (7.7) 20 (6.4) (8.0)
   Potential anaphylaxis 0 1 (1.2) 0 0 0 0 0 0 1 (0.3) (0.4)
  Hepatic 6 (7.0) 1 (1.2) 3 (3.8) 4 (5.1) 4 (4.3) 2 (2.0) 2 (2.2) 16 (4.9) (6.2) 13 (4.1) (5.2)
  Cerebrocardiovascular events‡, adjudicated 1 (1.2) 0 0 0 1 (1.1) 1 (1.0) 0 3 (0.9) (1.2) 3 (1.0) (1.2)
   MACE 0 0 0 0 1 (1.1) 0 0 0 1 (0.3) (0.4)
  Malignancies 0 1 (1.2) 0 0 0 0 0 2 (0.6) (0.8) 0
  Anterior uveitis 2 (2.3) 2 (2.3) 1 (1.3) 1 (1.3) 2 (2.2) 4 (4.1) 5 (5.6) 9 (2.8) (3.5) 11 (3.5) (4.4)
  Depression 0 0 0 0 0 1 (1.0) 1 (1.1) 1 (0.3) (0.4) 2 (0.6) (0.8)
  Crohn’s disease 1 (1.2) 1 (1.2) 0 0 0 0 0 2 (0.6) (0.8) 2 (0.6) (0.8)
  Ulcerative colitis 1 (1.2) 0 0 0 0 0 0 2 (0.6) (0.8) 0
  IBD not otherwise specified 0 0 1 (1.3) 0 0 0 0 2 (0.6) (0.8) 0
  Psoriasis 0 0 0 0 0 3 (3.1) 1 (1.1) 4 (1.2) (1.5) 1 (0.3) (0.4)
*IR calculated per 100 patient- years.
†Defined as events reported by ≥5% of all patients in either of the two studies in the ETP population.
‡Cerebrocardiovascular events included death, cardiac ischaemic events including myocardial infarction and hospitalisation for unstable angina, hospitalisation for heart failure, 
serious arrhythmia, resuscitated sudden death, cardiogenic shock, coronary revascularisation procedure, stroke/transient ischaemic attack, peripheral revascularisation procedure 
and peripheral arterial event and hospitalisation for hypertension.
ADA, adalimumab; AE, adverse event; bDMARD, biological disease- modifying antirheumatic drug; ETP, dose double- blind extended treatment period; IBD, inflammatory bowel 
disease; IR, incidence rate; IXE, IXE Q4W and IXE Q2W combined; MACE, major adverse cerebrocardiovascular events; PBO, placebo; IXE Q2W, ixekizumab 80 mg every 2 weeks; 
IXE Q4W, ixekizumab 80 mg every 4 weeks; SAE, serious adverse event; TEAE, treatment- emergent adverse event; TNFi, tumour necrosis factor inhibitor.
was considered related to treatment). There were no deaths 
during the ETP in either study.
Malignancy (bladder cancer) was reported by one patient 
(ADA/IXE) in COAST- V; the event was rated severe and led to 
study discontinuation. Depression was reported by two patients 
in COAST- W (both continued treatment); there were no events 
of suicide or attempted suicide in the ETP (one event of suicide 
occurred during the placebo- controlled period in a patient (IXE 
Q2W) with a history of depression).11 There were no events of 
grade 3/4 neutropenia in either study.
Cerebrocardiovascular events were reported by one patient in 
COAST- V and two patients in COAST- W. One patient (PBO/IXE) 
in COAST- W reported a major adverse cerebrocardiovascular 
event of acute myocardial infarction; the event was severe, 
resolved and did not lead to study nor treatment discontinuation. 
Allergic reactions/hypersensitivities were reported by 14 (4.3%) 
patients in COAST- V and 12 (4.3%) patients in COAST- W.
Infections were reported by 103 (31.3%) patients in COAST- V 
and 94 (33.5%) patients in COAST- W; most were mild or 
moderate in severity. Serious infections were reported by three 
patients (cellulitis, pneumonia and tonsillitis; all n=1 patient) 
in COAST- V and three patients (gastroenteritis, pneumonia and 
sinusitis; all n=1 patient) in COAST- W; one of these patients 
discontinued the study. Candida infection was reported by 
two patients (oesophageal candidiasis and fungal oesophagitis; 
both n=1 patient) in COAST- V and two patients (oesophageal 
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candidiasis and oral candidiasis; both n=1 patient) in COAST- W 
(all were mild or moderate in severity); one of these patients 
discontinued the study. Three Candida infection events resolved 
and the other was resolving at the time of patient discontinua-
tion. ISRs were reported by 42 (12.8%) patients in COAST- V and 
18 (6.4%) patients in COAST- W. Most were mild or moderate in 
severity; two were severe. One patient discontinued study drug 
due to an ISR.
AU was reported by 17 patients, 6 (1.8%) in COAST- V and 
11 (3.9%) in COAST- W; none were SAEs and 14 had a history 
of AU. One patient in COAST- W (IXE Q4W/IXE Q4W) discon-
tinued the study because of AU.
In COAST- V, two patients (with no prior diagnosis) reported 
Crohn’s disease and two patients with a prior diagnosis of ulcer-
ative colitis reported a flare (online supplementary table S6). All 
events were mild or moderate in severity; one patient discon-
tinued treatment. All events, except one, were adjudicated as 
‘probable’; one event of Crohn’s disease (ADA/IXE) was adjudi-
cated as ‘definitive’. There were no events of Crohn’s disease or 
ulcerative colitis in COAST- W.
All ixekizumab exposure safety population (weeks 0 to 52)
During the 52- week study periods of COAST- V and COAST- W 
(n=641), the pooled exposure- adjusted incidence rate per 100 
patient years (EAIR) of serious infections was 2.0 among patients 
treated with ixekizumab (table 3). Pooled EAIRs of Candida 
infection and grade 3/4 neutropenia were 1.0 and 0.2, respec-
tively. Corresponding EAIRs for Crohn’s disease, ulcerative 
colitis and IBD not otherwise specified (NOS) were 0.8, 0.4 and 
0.4, respectively (total IBD EAIR: 1.6). The EAIR for AU was 
3.9; 15/20 (75%) patients had a history of AU and 14/20 (70%) 
patients were from COAST- W. The pooled EAIR for psoriasis 
was 1.0. One patient had a major adverse cerebrocardiovascular 
event (acute myocardial infarction) and two malignancies were 
reported (acute promyelocytic leukaemia and bladder cancer).
Fewer ISRs were reported with IXE Q4W (9.2%) versus 
IXE Q2W (17.2%). The number of patients reporting an ISR 
decreased over time. Specifically, 6.4%, 3.8% and 3.4% of 
patients on IXE Q4W and 14.3%, 8.6% and 5.2% of patients 
on IXE Q2W reported an ISR from weeks 0–12, weeks 12–24 
and weeks 24–36, respectively. Few patients (IXE Q4W ≤1%; 
IXE Q2W approximately 3%) reported an ISR beyond week 36.
Treatment-emergent antidrug antibodies
TE- ADAs were detected during the 52- week study period 
in 23 (6.9%) patients in COAST- V and 27 (8.9%) patients in 
COAST- W. Most TE- ADA- positive patients had low titres 
(COAST- V, 18 (78%); COAST- W, 23 (85%)) and four patients 
(COAST- V, 1 (0.3%); COAST- W, 3 (1.0%)) were neutralising 
antibody positive. There were no associations between TE- ADA 
positivity and ASAS40 response, ISRs or allergic reaction/hyper-
sensitivity events.
dISCuSSIOn
In COAST- V and COAST- W, the significant improvements 
observed at week 1610 11 were sustained for up to 52 weeks 
with ixekizumab treatment as measured by ASAS40 responses 
and other efficacy outcomes assessing disease activity, func-
tion, objective inflammation, QoL, health status and overall 
functioning. The results for IXE Q4W and IXE Q2W were 
similar across endpoints. ASAS40 response rates in patients 
rerandomised from PBO rapidly increased to levels consistent 
with those seen with continuous ixekizumab treatment. Patients 
rerandomised from ADA to ixekizumab at week 16 achieved 
numerically greater response rates for ASAS40 and other effi-
cacy outcomes at week 52 than at week 16. Collectively, the data 
from COAST- V and COAST- W demonstrate that ixekizumab is 
an effective treatment in patients with active r- axSpA who are 
bDMARD- naive or TNFi- experienced.
In general, treatment responses were numerically smaller 
in TNFi- experienced (COAST- W) versus bDMARD- naive 
(COAST- V) patients, reflecting a more difficult to treat popula-
tion with prior treatment failure and more long- standing disease.
Currently approved biological therapies for axSpA include 
several TNFi and one IL- 17A antagonist. Although only head- 
to- head trials can fully assess the relative efficacy and safety of 
different treatments, the week 52 ASAS40 findings reported 
herein are consistent with those reported for TNFi in patients 
who were bDMARD- naive23–26 and for secukinumab in 
subgroups of patients who were bDMARD- naive or had previ-
ously failed TNFi treatment.27
The safety profile of ixekizumab during the ETP (week 16 
to 52) in both COAST- V and COAST- W is consistent with that 
observed during weeks 0 to 16.10 11 Discontinuation due to AEs 
was <4% in both studies, whereas <6% of patients reported 
SAEs. Most infections and ISRs were mild or moderate in 
severity and did not result in study discontinuation. ISRs were 
more frequent with IXE Q2W than IXE Q4W. Furthermore, ISRs 
were most frequently reported during the first 4 weeks of treat-
ment and decreased in frequency over time. During the 52- week 
study period, pooled EAIRs for Crohn’s disease, ulcerative 
colitis, IBD NOS, Candida infection and grade 3/4 neutropenia 
were ≤1 event/100 patient- years among patients treated with 
ixekizumab. Among patients who reported IBD events, most had 
a prior diagnosis of IBD or a gastrointestinal history potentially 
indicative of IBD. Fewer IBD events were reported with IXE 
Q2W versus IXE Q4W, and there was no apparent relationship 
between the length of ixekizumab exposure and IBD. Previous 
reports have indicated that the EAIR for AU in patients with AS 
ranges from 2.6 to 3.5 for patients treated with TNFi.28 The 
EAIR of AU reported herein is at the upper limit of this range, 
primarily driven by patients from the TNF- experienced popu-
lation. All but one patient were HLA- B27 positive, with the 
majority having a history of AU.
An important strength of these analyses is use of the most 
conservative methods of missing data imputation (NRI and 
mBOCF) for the primary analyses. Furthermore, as COAST- V 
and COAST- W exclusively enrolled bDMARD- naive and TNFi- 
experienced patients, respectively, both studies were fully 
powered for analyses in these populations. Notably, patients 
in COAST- W had very active disease (baseline ASDAS >4) and 
more than 30% had failed two prior TNFi. Another strength is 
the use of objective measures of inflammation, including MRI at 
week 52 (COAST- V only); to date, ixekizumab is the only IL- 17A 
antagonist for which short- term and long- term MRI clinical trial 
data are available. The ETP results are limited by the lack of any 
placebo or active control comparators.
In conclusion, ixekizumab provided sustained and clinically 
meaningful improvement in the signs and symptoms of active 
r- axSpA for up to 52 weeks in COAST- V and COAST- W, with 
a high rate of completion. The safety findings were consistent 
with the known safety profile of ixekizumab. These findings 
suggest that ixekizumab could be a treatment option for axSpA 
in patients who are bDMARD- naive or who have had a prior 
inadequate response or intolerance to TNFi.
184 Dougados M, et al. Ann Rheum Dis 2020;79:176–185. doi:10.1136/annrheumdis-2019-216118
Spondyloarthritis
Author affiliations
1Paris Descartes University; Department of Rheumatology, Hôpital Cochin; 
assistance Publique - Hôpitaux de Paris; inseRM (U1153), Clinical epidemiology and 
Biostatistics, PRes sorbonne Paris- Cité, Paris, France
2institute of Medicine, Chung shan Medical University; Department of internal 
Medicine, Chung shan Medical University Hospital; Graduate institute of integrated 
Medicine, China Medical University, Taichung, Taiwan
3amsterdam Rheumatology and Clinical immunology Center, amsterdam, The 
netherlands
4Charité Universitätsmedizin Berlin, Berlin, Germany
5Rheumazentrum Ruhrgebiet Herne, Ruhr- University Bochum, Bochum, Germany
6Ghent University Hospital, Gent, Belgium
7University of alberta, edmonton, alberta, Canada
8Brigham and Women’s Hospital and Harvard Medical school, Boston, 
Massachusetts, Usa
9Division of Rheumatology, University of Utah and salt lake City Veterans affairs 
Medical Centers, salt lake City, Utah, Usa
10Department of Orthopaedic Biomaterial science, Osaka University Graduate school 
of Medicine, suita, Osaka, Japan
11Oregon Health and science University, Portland, Oregon, Usa
12Department of Rheumatology, leiden University Medical Center, leiden, The 
netherlands
13eli lilly and Company, indianapolis, indiana, Usa
14University of California, san Francisco, California, Usa
Acknowledgements These results were presented in part at the european 
Congress of Rheumatology 2019, Madrid, spain (12–15 June). Medical writing 
assistance was provided by luke Carey, PhD, CMPP of Proscribe – envision Pharma 
Group, and was funded by eli lilly and Company. Proscribe’s services complied with 
international guidelines for Good Publication Practice (GPP3). The authors would like 
to thank all study participants and emily seem, eli lilly and Company, for assistance 
with statistical analyses.
Contributors all authors participated in the interpretation of study results, and in 
the drafting, critical revision and approval of the final version of the manuscript. MD, 
JC- CW, Js, FVdB, WPM, aD, DvdH, Xl, FZ and HC contributed to study conception 
and/or design. JC- CW, Rl, WPM, aD, DvdH, FZ, Xl and HC contributed to the 
acquisition of study results. MD, Rl, Js, Xl, FZ and HC contributed to the analysis of 
study results.
Funding The studies described in this manuscript were sponsored by eli lilly and 
Company, which was involved in the study design, data collection, data analysis and 
preparation of the manuscript.
Competing interests MD has served as a consultant and received research grants 
from abbVie, eli lilly and Company, Pfizer and UCB Pharma. JC- CW has served 
as a consultant and/or speaker and/or has received research grants from abbott, 
Bristol- Myers squibb, Celgene, Chugai, eisai, eli lilly and Company, Janssen, novartis, 
Pfizer, sanofi- aventis, TsH Taiwan and UCB Pharma. Rl has served as a consultant 
and/or advisor and/or has received research grants from abbVie, Bristol- Myers 
squibb, Celgene, eli lilly and Company, Janssen, Galapagos, Merck, novartis, Pfizer 
and UCB Pharma. Rl is the director of Rheumatology Consultancy BV, a company 
that was indirectly contracted by eli lilly and Company to perform read services 
for the COasT program. Js has served as a consultant and/or speaker for abbVie, 
Boehringer ingelheim, eli lilly and Company, Janssen, Merck, novartis, Pfizer, Roche 
and UCB Pharma. XB has served as a consultant and/or has received research 
grants from abbVie, Bristol- Myers squibb, Celgene, Janssen, MsD, novartis, Pfizer, 
Roche and UCB Pharma. FVdB has served as a consultant and/or speaker and/or 
has received research grants from abbVie, Bristol- Myers squibb, Celgene, eli lilly 
and Company, Janssen, Merck, novartis, Pfizer, sanofi and UCB Pharma. WPM has 
served as a consultant and/or received honoraria and/or research/educational grants 
from abbVie, Boehringer ingelheim, Celgene, eli lilly and Company, Galapagos, 
Janssen, novartis, Pfizer and UCB Pharma, and is Chief Medical Officer of CaRe 
arthritis limited. Je has served as a consultant and/or received research grants 
from abbVie, Boehringer ingelheim, eli lilly and Company, Janssen, novartis, Pfizer, 
Takeda and UCB Pharma. JaW has been a consultant and/or received research 
grants from abbVie, amgen, Celgene, eli lilly and Company, novartis, Pfizer and UCB 
Pharma. aD has been a consultant and/or received research support from abbVie, 
Bristol- Myers squibb, eli lilly and Company, Glaxo smith & Klein, Janssen, novartis, 
Pfizer and UCB Pharma. DvdH has been a consultant for abbVie, amgen, astellas, 
astraZeneca, Bristol- Myers squibb, Boehringer ingelheim, Celgene, Daiichi, eli lilly 
and Company, Galapagos, Gilead, Janssen, Merck, novartis, Pfizer, Regeneron, 
Roche, sanofi, Takeda and UCB Pharma and is a Director of imaging Rheumatology 
BV. TT has been a consultant and speaker for abbVie, astellas, Bristol- Myers squibb, 
eisai, eli lilly and Company, Janssen, Mitsubishi Tanabe, novartis, Pfizer and Takeda. 
Xl, FZ, CCB, GG and HC are current employees and shareholders of eli lilly and 
Company. lsG has been a consultant and/or received research grants/support from 
abbVie, amgen, eli lilly and Company, Galapagos, Janssen, novartis, Pfizer and UCB 
Pharma.
Patient consent for publication not required.
ethics approval Trial protocols were approved by ethics review boards at each 
study site. Trials were performed in accordance with the ethical principles of the 
Declaration of Helsinki.
Provenance and peer review not commissioned; externally peer reviewed.
data availability statement lilly provides access to all individual participant 
data collected during the trial, after anonymisation, with the exception of 
pharmacokinetic or genetic data. Data are available to request 6 months after the 
indication studied has been approved in the United states and the european Union 
and after primary publication acceptance, whichever is later. no expiration date 
of data requests is currently set once they are made available. access is provided 
after a proposal has been approved by an independent review committee identified 
for this purpose and after receipt of a signed data sharing agreement. Data and 
documents, including the study protocol, statistical analysis plan, clinical study report, 
blank or annotated case report forms, will be provided in a secure data sharing 
environment for up to 2 years per proposal. For details on submitting a request, see 
the instructions provided at www. clin ical stud ydat arequest. com.
Open access This is an open access article distributed in accordance with the 
Creative Commons attribution non Commercial (CC BY- nC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId ids
Walter P Maksymowych http:// orcid. org/ 0000- 0002- 1291- 1755
Désirée van der Heijde http:// orcid. org/ 0000- 0002- 5781- 158X
RefeRences
 1 sieper J, Poddubnyy D. axial spondyloarthritis. Lancet 2017;390:73–84.
 2 Gao X, Wendling D, Botteman MF, et al. Clinical and economic burden of extra- 
articular manifestations in ankylosing spondylitis patients treated with anti- tumor 
necrosis factor agents. J Med Econ 2012;15:1054–63.
 3 Boonen a, van der linden sM. The burden of ankylosing spondylitis. J Rheumatol 
Suppl 2006;78:4–11.
 4 Ward MM, Deodhar a, akl ea, et al. american College of Rheumatology/spondylitis 
association of america/spondyloarthritis research and treatment network 2015 
recommendations for the treatment of ankylosing spondylitis and nonradiographic 
axial spondyloarthritis. Arthritis Care Res 2016;68:151–66.
 5 van der Heijde D, Ramiro s, landewé R, et al. 2016 update of the asas- eUlaR 
management recommendations for axial spondyloarthritis. Ann Rheum Dis 
2017;76:978–91.
 6 sepriano a, Regel a, van der Heijde D, et al. efficacy and safety of biological and 
targeted- synthetic DMaRDs: a systematic literature review informing the 2016 update 
of the asas/eUlaR recommendations for the management of axial spondyloarthritis. 
RMD Open 2017;3:e000396.
 7 D’angelo s, Carriero a, Gilio M, et al. safety of treatment options for spondyloarthritis: 
a narrative review. Expert Opin Drug Saf 2018;17:475–86.
 8 Kenna TJ, Davidson si, Duan R, et al. enrichment of circulating interleukin-17- 
secreting interleukin-23 receptor- positive γ/δ T cells in patients with active ankylosing 
spondylitis. Arthritis Rheum 2012;64:1420–9.
 9 shen H, Goodall JC, Hill Gaston Js. Frequency and phenotype of peripheral blood 
Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 
2009;60:1647–56.
 10 van der Heijde D, Cheng- Chung Wei J, Dougados M, et al. ixekizumab, an interleukin- 
17a antagonist in the treatment of ankylosing spondylitis or radiographic axial 
spondyloarthritis in patients previously untreated with biological disease- modifying 
anti- rheumatic drugs (COasT- V): 16 week results of a phase 3 randomised, double- 
blind, active- controlled and placebo- controlled trial. Lancet 2018;392:2441–51.
 11 Deodhar a, Poddubnyy D, Pacheco- Tena C, et al. efficacy and safety of ixekizumab 
in the treatment of radiographic axial spondyloarthritis: sixteen- week results rrom 
a phase iii randomized, double- blind, placebo- controlled trial in patients with prior 
inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis 
Rheumatol 2019;71:599–611.
 12 Rudwaleit M, van der Heijde D, landewé R, et al. The development of assessment of 
spondyloarthritis international society classification criteria for axial spondyloarthritis 
(part ii): validation and final selection. Ann Rheum Dis 2009;68:777–83.
 13 sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis 
international society (asas) handbook: a guide to assess spondyloarthritis. Ann 
Rheum Dis 2009;68 suppl 2:ii1–44.
 14 Machado PMMC, landewé RBM, van der Heijde DM. endorsement of definitions of 
disease activity states and improvement scores for the ankylosing spondylitis Disease 
activity score: results from OMeRaCT 10. J Rheumatol 2011;38:1502–6.
 15 Garrett s, Jenkinson T, Kennedy lG, et al. a new approach to defining disease status 
in ankylosing spondylitis: the Bath ankylosing spondylitis Disease activity index. J 
Rheumatol 1994;21:2286–91.
185Dougados M, et al. Ann Rheum Dis 2020;79:176–185. doi:10.1136/annrheumdis-2019-216118
Spondyloarthritis
 16 Calin a, Garrett s, Whitelock H, et al. a new approach to defining functional ability in 
ankylosing spondylitis: the development of the Bath ankylosing spondylitis Functional 
index. J Rheumatol 1994;21:2281–5.
 17 Ware Je, snow KK, Kosinski M, et al. Sf-36 health survey: manual and interpretation 
guide. 2nd ed. lincoln, Ri: QualityMetric, 2000.
 18 Kiltz U, van der Heijde D, Boonen a, et al. The asas Health index (asas Hi) - a new 
tool to assess the health status of patients with spondyloarthritis. Clin Exp Rheumatol 
2014;32:s-105-8.
 19 Kiltz U, van der Heijde D, Boonen a, et al. Development of a health index in patients 
with ankylosing spondylitis (asas Hi): final result of a global initiative based on the 
iCF guided by asas. Ann Rheum Dis 2015;74:830–5.
 20 Maksymowych WP, inman RD, salonen D, et al. spondyloarthritis Research Consortium 
of Canada magnetic resonance imaging index for assessment of spinal inflammation 
in ankylosing spondylitis. Arthritis Rheum 2005;53:502–9.
 21 Dougados M, simon P, Braun J, et al. asas recommendations for collecting, 
analysing and reporting nsaiD intake in clinical trials/epidemiological studies in axial 
spondyloarthritis. Ann Rheum Dis 2011;70:249–51.
 22 Gower- Rousseau C, salomez Jl, Dupas Jl, et al. incidence of inflammatory bowel 
disease in northern France (1988-1990). Gut 1994;35:1433–8.
 23 van der Heijde D, schiff MH, sieper J, et al. adalimumab effectiveness for the 
treatment of ankylosing spondylitis is maintained for up to 2 years: long- term results 
from the aTlas trial. Ann Rheum Dis 2009;68:922–9.
 24 Davis JC, van der Heijde DM, Braun J, et al. sustained durability and tolerability 
of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 
2005;64:1557–62.
 25 Braun J, Deodhar a, inman RD, et al. Golimumab administered subcutaneously every 4 
weeks in ankylosing spondylitis: 104- week results of the GO- Raise study. Ann Rheum 
Dis 2012;71:661–7.
 26 sieper J, landewé R, Rudwaleit M, et al. effect of certolizumab pegol over ninety- six 
weeks in patients with axial spondyloarthritis: results from a phase iii randomized 
trial. Arthritis Rheumatol 2015;67:668–77.
 27 sieper J, Deodhar a, Marzo- Ortega H, et al. secukinumab efficacy in anti- TnF- naive 
and anti- TnF- experienced subjects with active ankylosing spondylitis: results from the 
MeasURe 2 study. Ann Rheum Dis 2017;76:571–92.
 28 Deodhar a, Miceli- Richard C, Baraliakos X, et al. low incidence of both new- onset 
and flares of uveitis in secukinumab- treated patients with ankylosing spondylitis: 
clinical trial and post- marketing safety analysis. Ann Rheum Dis 2018;77(suppl 
2):999.
